Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$6.25 - $11.11 $186,425 - $331,389
29,828 New
29,828 $302,000
Q2 2023

Aug 14, 2023

SELL
$6.36 - $11.47 $75,308 - $135,816
-11,841 Reduced 76.76%
3,585 $29,000
Q1 2023

May 15, 2023

SELL
$7.03 - $11.53 $47,466 - $77,850
-6,752 Reduced 30.44%
15,426 $111,000
Q4 2022

Feb 14, 2023

BUY
$8.32 - $13.21 $184,520 - $292,971
22,178 New
22,178 $196,000
Q4 2021

Feb 14, 2022

BUY
$26.55 - $40.57 $497,945 - $760,890
18,755 Added 68.02%
46,327 $1.23 Million
Q2 2021

Aug 16, 2021

BUY
$31.29 - $56.64 $777,431 - $1.41 Million
24,846 Added 911.45%
27,572 $1.56 Million
Q1 2021

May 17, 2021

SELL
$39.71 - $90.58 $19,219 - $43,840
-484 Reduced 15.08%
2,726 $114,000
Q4 2020

Feb 16, 2021

BUY
$27.07 - $84.35 $9,988 - $31,125
369 Added 12.99%
3,210 $225,000
Q3 2020

Nov 16, 2020

SELL
$28.06 - $37.16 $104,327 - $138,160
-3,718 Reduced 56.69%
2,841 $80,000
Q2 2020

Aug 14, 2020

SELL
$18.5 - $34.34 $179,986 - $334,093
-9,729 Reduced 59.73%
6,559 $194,000
Q1 2020

May 15, 2020

BUY
$14.88 - $32.78 $80,604 - $177,569
5,417 Added 49.83%
16,288 $323,000
Q4 2019

Feb 14, 2020

BUY
$19.49 - $32.63 $171,336 - $286,850
8,791 Added 422.64%
10,871 $322,000
Q3 2019

Nov 14, 2019

BUY
$22.49 - $26.81 $26,628 - $31,743
1,184 Added 132.14%
2,080 $47,000
Q2 2019

Aug 14, 2019

SELL
$20.48 - $27.76 $638,525 - $865,501
-31,178 Reduced 97.21%
896 $22,000
Q4 2018

Feb 14, 2019

BUY
$18.19 - $31.79 $517,814 - $904,965
28,467 Added 789.22%
32,074 $730,000
Q3 2018

Nov 14, 2018

BUY
$27.65 - $38.39 $31,548 - $43,802
1,141 Added 46.27%
3,607 $115,000
Q2 2018

Aug 14, 2018

SELL
$31.4 - $41.01 $479,132 - $625,771
-15,259 Reduced 86.09%
2,466 $88,000
Q1 2018

May 15, 2018

BUY
$29.84 - $44.08 $528,914 - $781,318
17,725 New
17,725 $588,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $92.1M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.